|
|
|
| Curative Effect of Pemetrexed Combined with Cisplatin on Advanced Non-small Cell Lung Cancer and the Influences onToxicity and 1-year Survival Rate |
| QIU Pei, et al |
| West China Hospital of Sichuan University, Sichuan Chengdu 610041, China |
|
|
|
|
Abstract Objective: To explore curative effect and safety of pemetrexed combined with cisplatin on advanced non-small cell lung cancer (NSCLC) and the influences on 1-year survival rate. Methods: A retrospective analysis was performed on related data of 85 patients with advanced NSCLC who were admitted to the hospital from June 2016 to June 2018. Patients who were treated with pemetrexed combined with cisplatin or docetaxel combined with cisplatin were included into pemetrexed group (n=42) and docetaxel group (n=43), respectively. The short-term curative effect, changes in tumor marker levels before and after treatment, incidence of toxicity, and long-term curative effect were compared between the two groups. Results: The response rate of treatment in pemetrexed group was higher than that in docetaxel group (54.76% vs 48.84% (P>0.05). The disease control rate in pemetrexed group was significantly higher than that in docetaxel group (92.86% vs 81.40%) (P<0.05). After treatment, levels of tumor markers such as NSE and CA125 in both groups were significantly decreased (P<0.05). After treatment, levels of four tumor markers in pemetrexed group were significantly lower than those in docetaxel group (P<0.05). The incidence of toxicity such as thrombocytopenia, gastrointestinal discomfort, abnormal liver function, anemia and leukopenia in pemetrexed group was lower than that in docetaxel group. There were significant differences in incidence of various toxicity except for abnormal liver function (P<0.05). There was no significant difference in metastatic rate of half a year disease progression between the two groups (P>0.05). The metastatic rate of 1-year disease progression in pemetrexed group was significantly lower than that in docetaxel group (P<0.05). Kaplan-Merier results showed that 1-year survival rate in pemetrexed group was significantly higher than that in docetaxel group (78.6% vs 53.5%). (Log-rank χ2= 5.297, P<0.05). Conclusion: The short-term effective rate of pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer is equivalent to that of docetaxel combined with cisplatin, but its disease control rate and long-term effect are better, and the incidence of complications is low, which can significantly reduce the level of tumor markers.
|
|
|
|
|
|
[1] Herbst R S,Morgensztern D,Boshoff C.The biology and management of non-small cell lung cancer.[J].Nat,2018,553(7689):446~454.
[2] Fehringer G,Brenner D R,Zhang Z F,et al.Alcohol and lung cancer risk among never smokers:a pooled analysis from the international lung cancer consortium and the SYNERGY study[J].Int Cancer,2017,140(9):1976~1984.
[3] Carbone D P,Reck,Martin,Paz-Ares,Luis,et al.First-line nivolumab in stage IV or recurrent non-small-cell lung cancer[J].N Engl Med,2017,39(25):2415~2426.
[4] Niu Y,Feng M,Huang W,et al.Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2[J].Mol Cancer,2017,16(1):5.
[5] Yuwen D L,Sheng B B,Liu J,et al.MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer.[J].Riv Eur Sci Med Farmacol,2017,21(11):2650~2658.
[6] Xiao H,Liu Y,Liang P,et al.TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis[J].Cell&Biosci,2018,8(1):23~33.
[7] 王临英.培美曲塞联合顺铂治疗非小细胞肺癌临床观察[J].中华肿瘤防治杂志,2016,23(1):100~101.
[8] 张雅军,徐锋,韩纪昌,等.培美曲塞联合紫杉醇和顺铂治疗非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(15):1396~1399. |
|
|
|
2020, Vol. 26 
